Cerca Biotech, an oncology and women’s health diagnostics firm, has announced exclusive distribution agreements with four key European partners for MammaTyper – a molecular diagnostic test to subtype breast cancer.
Italian firm AB Analytica, Omegen Molecular from Istanbul, Romanian firm Diamedix and Buhlmann Labs in Switzerland will be working with Cerca Biotech to distribute MammaTyper across much of Southern and Central Europe.
MammaTyper applies 21st Century RT-qPCR technology to quantify mRNA levels of four essential breast cancer biomarkers (ER, PgR, HER2, and Ki-67).
The company says it avoids many of the common pre-analytical errors in the pathology lab, especially for proliferation marker Ki-67 - critical in luminal subtyping and prognosis.
The addition of these key partners brings a wealth of clinical and technical expertise to the MammaTyper team covering Italy, Austria, Switzerland, Turkey, Romania, Republic of Moldova, Ukraine, Bulgaria and Georgia. Cerca Biotech also has plans to bring MammaTyper to the Nordics, Germany, the UK and Benelux in the near future and is actively seeking partners in these regions.
Richard Hughes, commercial director at Cerca Biotech, said: “We know that MammaTyper has the potential to change the way breast cancer tissue is subtyped, enabling pathologists and oncologists to have utter confidence in the results and therefore their treatment plans for patients. We are really pleased that our new partners have recognised this and have come on board to help ensure that all women have the best chance of beating breast cancer.”
